ArticleInternational journal of clinical and experimental pathology2018
SEC24A stimulates oncogenicity of human gastric cancer cells.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- ING5-mediated regulation of lung cancer progression via the OIP5-AS1/miR-381-3p/SEC24A axis.Translational cancer research · 2025Article
- Pan-cancer analysis reveals age-associated genetic alterations in protein domains.American journal of human genetics · 2025Article
- Exploring the Clinical Implications of RPL3 Presence in BRCA-Associated Cancers: Unraveling the Interplay With Cancer Immunity.Clinical Medicine Insights. Oncology · 2024Article
- Export Control: Post-transcriptional Regulation of the COPII Trafficking Pathway.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a worldwide health concern and is the second common malignancy. Despite rapid progression in diagnostic and therapeutic approaches over the past decades, the molecular mechanisms underlying the development and progression of GC remain unclear. SEC24 homolog A, COPII coat complex component (SEC24A) belongs to a protein family that are homologous to yeast SEC24, and is critical for neural tube closure. Thus, we focus on the relation of SEC24A and human GC cells. In our study, we found that SEC24A was highly expressed in tumor tissue compared to non-tumor tissue. Furthermore, less aggressive behavior was observed in the si-SEC24A transfected human GC cells (SGC-7901 and BGC-823). On the other hand, we have also found that over-expression of miR-101-3p down-regulated the expression of SEC24A. SEC24A played a role in promoting invasion and metastasis of human GC cells.
Indexed as
Identifiers
31949794PMC6962814W3026567668What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.